Pharmacyclics, Inc. (PCYC), Genomic Health, Inc. (GHDX)…Mega-Hedge Fund Focusing on The Life Sciences

Last but not least, is Incyte Corporation (NASDAQ:INCY), a biopharmaceutical company whose main product is Jakafi for the treatment myelofibrosis, a bone marrow disorder that can lead to severe anemia and an enlarged spleen and liver.  But because myelofibrosis does not affect many individuals, the revenue potential for Incyte Corporation (NASDAQ:INCY) is limited.  Although Incyte Corporation (NASDAQ:INCY) has had very strong revenue growth and earnings were positive for 4Q (+$0.14 vs -$0.44 for the year ago period), the limited revenue potential for its product is worth paying attention to.

Although it’s hard for non-life science enthusiasts to understand what many of these companies actually do, it’s not hard to understand why Baker Brothers Advisors has packed its portfolio with some of the most innovative, ground-breaking companies in the biopharmaceutical industry. And the large stake it’s placed in each company is a vote of confidence from a hedge fund that obviously knows its healthcare stocks, from Incyte’s top line growth, to the attractiveness of Genomic, Synageva, Seattle Genetics, Pharmacyclics.

Disclosure: none